Article

AMO, Alcon in dispute over phaco patents

Santa Ana, CA-Advanced Medical Optics (AMO) is claiming, in a complaint filed in federal court, that Alcon's Infiniti and Series 20000 Legacy phacoemulsification systems infringe AMO patents for advanced fluidics technologies in the removal of cataracts.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Subscribe Now!
Related Videos
(Image credit: Ophthalmology Times) NeuroOp Guru: Cranial nerve six palsy with chemosis is a critical clue to cavernous carotid fistula
(Image credit: Ophthalmology Times) Neda Shamie_Controversies in Modern Eye Care 2025
(Image credit: Ophthalmology Times) World Cornea Congress IX: Epi-on and accelerated crosslinking with Kenneth Beckman, MD
(Image credit: Ophthalmology Times) The synergy of cornea, cataract, and refractive surgery through the decades: insights from George O. Waring IV, MD
Related Content
Opus Genetics reports 1-month pediatric results in gene therapy for inherited retinal disease
April 8th 2025

Opus Genetics reports 1-month pediatric results in gene therapy for inherited retinal disease

2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco
December 13th 2024

California dreaming: 2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco

(Image courtesy of the Australian Society of Ophthalmologists)
April 8th 2025

Breaking barriers: Australian Society of Ophthalmologists’ first woman CEO steps up

EnVision Summit 2025: Advancing Ophthalmology and Optometry Together
November 19th 2024

Connect, learn, and innovate in a family-friendly atmosphere: What to expect at EnVision Summit 2025

Early-onset atopic dermatitis linked to higher risk of pediatric uveitis
April 8th 2025

Early-onset atopic dermatitis linked to higher risk of pediatric uveitis

Alumis and Acelyrin file a definitive proxy statement for proposed merger
April 7th 2025

Alumis and Acelyrin file a definitive proxy statement for proposed merger

© 2025 MJH Life Sciences

All rights reserved.